Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid TumorsMatthew D. Hellmann, Toshihiko Doi, Toshio Shimizu et al.|Clinical Cancer Research|2021Cited by 111
A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)Krish Patel, Gilles Salles, Tycel Phillips et al.|Blood|2025Cited by 0